Skip to main
OPT
OPT logo

Opthea (OPT) Stock Forecast & Price Target

Opthea (OPT) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 25%
Hold 25%
Sell 13%
Strong Sell 0%

Bulls say

Opthea Ltd is focused on developing innovative biologic therapies, particularly OPT-302, aimed at treating eye diseases linked to blood and lymphatic vessel growth. Positive preliminary results from the Phase 2b trial demonstrate significant visual acuity improvements, with a notable 5.7 letter gain in certain patient subgroups, potentially exceeding the efficacy thresholds required for successful pivotal trial outcomes. As the company heads towards the Phase 3 COAST trial's topline results expected in early Q2 CY2025, optimism grows regarding the broader adoption of its treatments, underpinned by supportive payer sentiment around meaningful vision improvement metrics.

Bears say

Opthea Ltd reported a substantial net loss of $131.9 million, or $0.11 per share, for the first half of FY 25, indicating significant financial challenges. The company's outlook remains negative due to critical risks, including the potential failure of its developmental candidate OPT-302 to meet revenue expectations, difficulties in securing the necessary capital resources for its operations, and ongoing uncertainty in the development and commercialization of its products. These factors collectively raise concerns about the company's ability to achieve sustainable growth and profitability in the highly competitive medical technology and healthcare sector.

Opthea (OPT) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 25% recommend Buy, 25% suggest Holding, 13% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Opthea and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Opthea (OPT) Forecast

Analysts have given Opthea (OPT) a Buy based on their latest research and market trends.

According to 8 analysts, Opthea (OPT) has a Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Opthea (OPT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.